Logo

American Heart Association

  207
  0


Final ID:

Discussant: YELLOW III

  • Mora, Samia  ( BRIGHAM AND WOMENS HOSPITAL , Boston , Massachusetts , United States )
  • Kramer, Christopher  ( Univ. of Virginia Health System , Charlottesville , Virginia , United States )
  • Author Disclosures:
    Samia Mora: DO have relevant financial relationships ; Royalties/Patent Beneficiary:co-inventor on patent application on glycosylation and cardiovascular disease issued to Genos and Brigham and Women's Hospital:Active (exists now) | Christopher Kramer: DO have relevant financial relationships ; Research Funding (PI or named investigator):BMS:Active (exists now) ; Research Funding (PI or named investigator):Cytokinetics:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Featured Science: Novel Approaches to Managing Lipid Risk

Saturday, 11/16/2024 , 01:30PM - 02:45PM

Featured Science

More abstracts on this topic:
Transcriptomic Signatures and Predictors of Evolocumab Added to Maximum Statin Therapy Based on Intra-Coronary Plaque Characteristics: YELLOW III Study

Kini Annapoorna, Krishnamoorthy Parasuram, Hooda Amit, Minatoguchi Shingo, Baruah Nimisha, Pineda Derek, Chen Vivian, Ellis Ethan, Hahn Aana, Krishnan Prakash, Moreno Pedro, Vengrenyuk Yuliya, Mehran Roxana, Sebra Robert, Zhou Xiaobo, Narula Jagat, Sharma Samin, Liu Jiajia, Yasumura Keisuke, Mandava Aishwaria, Shah Hardik, Sweeny Joseph, Khera Sahil, Kapur Vishal

Long-term Efficacy of Lerodalcibep in 1,468 Patients at Very High and High Risk for CVD in the 72 week Open-Label Extension Trial

Kereiakes Dean, Fourie Nyda, Scott Russell, Asprusten Emil, Yalim Zafer, Vest Jeff, Kallend David, Stein Evan

You have to be authorized to contact abstract author. Please, Login
Not Available